Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress Signaling Pathways

Hyperlipidemia associated with the HIV protease inhibitor (PI), the major component of highly active antiretroviral treatment (HAART) for HIV infection, has stimulated interest in developing new agents that minimize these side effects in the clinic. HIV integrase inhibitor is a new class of anti-HIV...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Cao, Risheng, Hu, Yiqiao, Wang, Yun, Gurley, Emily C., Studer, Elaine J., Wang, Xuan, Hylemon, Phillip B., Pandak, William M., Sanyal, Arun J., Zhang, Luyong, Zhou, Huiping
Format: Artigo
Idioma:Inglês
Publicat: The American Society for Pharmacology and Experimental Therapeutics 2010
Matèries:
Gastrointestinal, Hepatic, Pulmonary, and Renal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913777/
https://ncbi.nlm.nih.gov/pubmed/20472667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.110.168484
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars